Personal Genome Diagnostics Inc.
CAGE Code: 6VMQ1
NCAGE Code: 6VMQ1
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 963427120
Summary
Personal Genome Diagnostics Inc. is an Active Commercial Supplier with the Cage Code 6VMQ1 and is tracked by Dun & Bradstreet under DUNS Number 963427120..
Address
3600 Boston St 10,
Baltimore MD 21224-5729
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Graybar Electric Company, Inc. Gvb Enterprises Reville Services Vicks Consulting Llc Safety-Kleen Corp Best Western Hotel Bobker Bearing Amilburn Co Yankee Engineering Co Inc Transunion Llc Century Autoline Metal Lubricants Merico Sales Inc Inphomation Communications Inc Morris James B Enterprise Banah Construction Crook H E Co Inc Maryland Shipbuilding And Drydock Co Alexanders Moving & Storage Eastern Broad Spectrum Optics Llc Whitehead Metals Inc
Frequently Asked Questions (FAQ) for CAGE 6VMQ1
- What is CAGE Code 6VMQ1?
- 6VMQ1 is the unique identifier used by NATO Organizations to reference the physical entity known as Personal Genome Diagnostics Inc. located at 3600 Boston St 10,, Baltimore MD 21224-5729, United States.
- Who is CAGE Code 6VMQ1?
- 6VMQ1 refers to Personal Genome Diagnostics Inc. located at 3600 Boston St 10,, Baltimore MD 21224-5729, United States.
- Where is CAGE Code 6VMQ1 Located?
- CAGE Code 6VMQ1 is located in Baltimore, MD, USA.
Contracting History for CAGE 6VMQ1 Most Recent 25 Records
- 36C24519N0144
- Genomic Testing Services
- 23 Oct 2018
- Genomic Testing Services
- 245-Network Contract Ofc 5(00245)
- Department Of Veterans Affairs (Va)
- $1,805,400.00
- Department Of Veterans Affairs (Va)
- VA24116J0465
- Genomic Tumor Analysis
- 20 Aug 2019
- Genomic Tumor Analysis
- 241-Network Contract Ofc 01(00241)
- Department Of Veterans Affairs (Va)
- $49,838.00
- Department Of Veterans Affairs (Va)
- 36C26320P0570
- Uac - Molecular Tissue Testing
- 1 May 2020
- Uac - Molecular Tissue Testing
- 263-Nco 23 Consolidate Contr(00263)
- Department Of Veterans Affairs (Va)
- $1,990.00
- Department Of Veterans Affairs (Va)
- VA24517J1380
- Igf::Ot::Igf Oncology Testing Services
- 28 Sep 2017
- Igf::Ot::Igf Oncology Testing Services
- 245-Network Contract Office 5 (36C2
- Department Of Veterans Affairs (Va)
- $3,627,950.00
- Department Of Veterans Affairs (Va)
- VA24117J1089
- P00001 Accession 64 Gene Plasmid Assay, Plasmaselect; Modify And Supplement Distribution Of Clinical Reports And Clarify File Format Types. P00001. The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-Derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Healthcare System. The Contractor Shall Provide Targeted Sequencing Of Dna Fragments Known To Harbor Mutations In Cancer Specimens (Commonly Referred To As A Mutation Panel). The Number Of Dna Segments Sequenced Varies By The Laboratory And Assay Performed. Mutations In The Dna Can Either Be Inferred Against A Laboratory `Reference Sequence Or Can Be Determined By Sequencing Of Patient Germ-Line Dna Obtained From Adjacent Normal Tissue Or Peripheral Blood. The Contractors Shall Provide Sequencing Of The Whole Exome Of Cancer Specimens, With Mutations Identified By Comparison Against A Laboratory `Reference Sequence Or Germ-Line Dna As Described Above. The Contracotr Shall Provide Sequencing Of The Cancer Specimen Rna Or `Transcriptome . This Strategy Can Be Combined With Either Targeted Or Whole Exome Dna Sequencing. Products Of The Testing Returned To The Va Include All Sequence Data Including Raw Test Data (Fast-Q, Bam, Read Quality Files And Variant Call Files) And A Report Of Important Mutations And Their Significance To Be Returned To The Medical Record. Mutations Found In The Tumor Sample Will Be Annotated So That Clinicians Can Gain An Understanding Of Their Meaning. The Laboratory Shall Specify How This Annotation Will Be Performed And In Particular, What Knowledge Base Will Be Used To Generate The Annotations. The Contractor Shall Maintains An Up-To-Date Knowledge Base And Must Be Able To Update Annotations Of A Patient Report Upon Request. The Contractor Shall At All Times Maintain A Secure Environment And Practice Covering All Protected Health Information (Phi).
- 19 Aug 2019
- P00001 Accession 64 Gene Plasmid Assay, Plasmaselect; Modify And Supplement Distribution Of Clinical Reports And Clarify File Format Types. P00001. The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-Derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Healthcare System. The Contractor Shall Provide Targeted Sequencing Of Dna Fragments Known To Harbor Mutations In Cancer Specimens (Commonly Referred To As A Mutation Panel). The Number Of Dna Segments Sequenced Varies By The Laboratory And Assay Performed. Mutations In The Dna Can Either Be Inferred Against A Laboratory `Reference Sequence Or Can Be Determined By Sequencing Of Patient Germ-Line Dna Obtained From Adjacent Normal Tissue Or Peripheral Blood. The Contractors Shall Provide Sequencing Of The Whole Exome Of Cancer Specimens, With Mutations Identified By Comparison Against A Laboratory `Reference Sequence Or Germ-Line Dna As Described Above. The Contracotr Shall Provide Sequencing Of The Cancer Specimen Rna Or `Transcriptome . This Strategy Can Be Combined With Either Targeted Or Whole Exome Dna Sequencing. Products Of The Testing Returned To The Va Include All Sequence Data Including Raw Test Data (Fast-Q, Bam, Read Quality Files And Variant Call Files) And A Report Of Important Mutations And Their Significance To Be Returned To The Medical Record. Mutations Found In The Tumor Sample Will Be Annotated So That Clinicians Can Gain An Understanding Of Their Meaning. The Laboratory Shall Specify How This Annotation Will Be Performed And In Particular, What Knowledge Base Will Be Used To Generate The Annotations. The Contractor Shall Maintains An Up-To-Date Knowledge Base And Must Be Able To Update Annotations Of A Patient Report Upon Request. The Contractor Shall At All Times Maintain A Secure Environment And Practice Covering All Protected Health Information (Phi).
- 241-Network Contract Ofc 01(00241)
- Department Of Veterans Affairs (Va)
- $349,600.00
- Department Of Veterans Affairs (Va)
- 36C24518N3844
- Oncology Testing Services
- 11 May 2020
- Oncology Testing Services
- 245-Network Contract Office 5 (36C2
- Department Of Veterans Affairs (Va)
- $123,550.00
- Department Of Veterans Affairs (Va)
- HHSN261201600005C
- Igf::Ot::Igf Sbir Phase I Topic 354
- 20 Dec 2017
- Igf::Ot::Igf Sbir Phase I Topic 354
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $222,994.00
- Department Of Health And Human Services (Hhs)
- 36C24518N3844
- Igf::Ot::Igf Oncology Testing Services
- 19 Sep 2018
- Igf::Ot::Igf Oncology Testing Services
- 245-Network Contract Office 5 (36C2
- Department Of Veterans Affairs (Va)
- $123,550.00
- Department Of Veterans Affairs (Va)
- VA24116J2218
- Genomic Tumor Analysis
- 20 Aug 2019
- Genomic Tumor Analysis
- 241-Network Contract Ofc 01(00241)
- Department Of Veterans Affairs (Va)
- $437,100.00
- Department Of Veterans Affairs (Va)
- 36C24519N0144
- Genomic Testing Services
- 24 Jan 2019
- Genomic Testing Services
- 245-Network Contract Ofc 5(00245)
- Department Of Veterans Affairs (Va)
- $1,805,400.00
- Department Of Veterans Affairs (Va)
- 36C26320P0569
- Uac - Molecular Tissue Testing
- 1 May 2020
- Uac - Molecular Tissue Testing
- 263-Nco 23 Consolidate Contr(00263)
- Department Of Veterans Affairs (Va)
- $1,990.00
- Department Of Veterans Affairs (Va)
- VA24517J1380
- Oncology Testing Services
- 12 May 2020
- Oncology Testing Services
- 245-Network Contract Office 5 (36C2
- Department Of Veterans Affairs (Va)
- $3,627,950.00
- Department Of Veterans Affairs (Va)
- VA24114J2145
- Igf::Ot::Igf The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-Derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Healthcare System. The Contractor Shall Provide Targeted Sequencing Of Dna Fragments Known To Harbor Mutations In Cancer Specimens (Commonly Referred To As A Mutation Panel). The Number Of Dna Segments Sequenced Varies By The Laboratory And Assay Performed. Mutations In The Dna Can Either Be Inferred Against A Laboratory `Reference Sequence Or Can Be Determined By Sequencing Of Patient Germ-Line Dna Obtained From Adjacent Normal Tissue Or Peripheral Blood. The Contractors Shall Provide Sequencing Of The Whole Exome Of Cancer Specimens, With Mutations Identified By Comparison Against A Laboratory `Reference Sequence Or Germ-Line Dna As Described Above. The Contracotr Shall Provide Sequencing Of The Cancer Specimen Rna Or `Transcriptome . This Strategy Can Be Combined With Either Targeted Or Whole Exome Dna Sequencing. Products Of The Testing Returned To The Va Include All Sequence Data Including Raw Test Data (Fast-Q, Bam, Read Quality Files And Variant Call Files) And A Report Of Important Mutations And Their Significance To Be Returned To The Medical Record. Mutations Found In The Tumor Sample Will Be Annotated So That Clinicians Can Gain An Understanding Of Their Meaning. The Laboratory Shall Specify How This Annotation Will Be Performed And In Particular, What Knowledge Base Will Be Used To Generate The Annotations. The Contractor Shall Maintains An Up-To-Date Knowledge Base And Must Be Able To Update Annotations Of A Patient Report Upon Request. The Contractor Shall At All Times Manintain A Secure Environment And Practice Covering All Protected Health Information (Phi).
- 26 Dec 2018
- Igf::Ot::Igf The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-Derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Healthcare System. The Contractor Shall Provide Targeted Sequencing Of Dna Fragments Known To Harbor Mutations In Cancer Specimens (Commonly Referred To As A Mutation Panel). The Number Of Dna Segments Sequenced Varies By The Laboratory And Assay Performed. Mutations In The Dna Can Either Be Inferred Against A Laboratory `Reference Sequence Or Can Be Determined By Sequencing Of Patient Germ-Line Dna Obtained From Adjacent Normal Tissue Or Peripheral Blood. The Contractors Shall Provide Sequencing Of The Whole Exome Of Cancer Specimens, With Mutations Identified By Comparison Against A Laboratory `Reference Sequence Or Germ-Line Dna As Described Above. The Contracotr Shall Provide Sequencing Of The Cancer Specimen Rna Or `Transcriptome . This Strategy Can Be Combined With Either Targeted Or Whole Exome Dna Sequencing. Products Of The Testing Returned To The Va Include All Sequence Data Including Raw Test Data (Fast-Q, Bam, Read Quality Files And Variant Call Files) And A Report Of Important Mutations And Their Significance To Be Returned To The Medical Record. Mutations Found In The Tumor Sample Will Be Annotated So That Clinicians Can Gain An Understanding Of Their Meaning. The Laboratory Shall Specify How This Annotation Will Be Performed And In Particular, What Knowledge Base Will Be Used To Generate The Annotations. The Contractor Shall Maintains An Up-To-Date Knowledge Base And Must Be Able To Update Annotations Of A Patient Report Upon Request. The Contractor Shall At All Times Manintain A Secure Environment And Practice Covering All Protected Health Information (Phi).
- 241-Network Contract Ofc 01(00241)
- Department Of Veterans Affairs (Va)
- $189,000.00
- Department Of Veterans Affairs (Va)
- VA24117J1763
- Genomic Analysis Of Cancerous Tumor Tissue
- 19 Aug 2019
- Genomic Analysis Of Cancerous Tumor Tissue
- 241-Network Contract Ofc 01(00241)
- Department Of Veterans Affairs (Va)
- $449,600.00
- Department Of Veterans Affairs (Va)
- VA24117J0678
- The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-Derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Healthcare System. The Contractor Shall Provide Targeted Sequencing Of Dna Fragments Known To Harbor Mutations In Cancer Specimens (Commonly Referred To As A Mutation Panel). The Number Of Dna Segments Sequenced Varies By The Laboratory And Assay Performed. Mutations In The Dna Can Either Be Inferred Against A Laboratory `Reference Sequence Or Can Be Determined By Sequencing Of Patient Germ-Line Dna Obtained From Adjacent Normal Tissue Or Peripheral Blood. The Contractors Shall Provide Sequencing Of The Whole Exome Of Cancer Specimens, With Mutations Identified By Comparison Against A Laboratory `Reference Sequence Or Germ-Line Dna As Described Above. The Contracotr Shall Provide Sequencing Of The Cancer Specimen Rna Or `Transcriptome . This Strategy Can Be Combined With Either Targeted Or Whole Exome Dna Sequencing. Products Of The Testing Returned To The Va Include All Sequence Data Including Raw Test Data (Fast-Q, Bam, Read Quality Files And Variant Call Files) And A Report Of Important Mutations And Their Significance To Be Returned To The Medical Record. Mutations Found In The Tumor Sample Will Be Annotated So That Clinicians Can Gain An Understanding Of Their Meaning. The Laboratory Shall Specify How This Annotation Will Be Performed And In Particular, What Knowledge Base Will Be Used To Generate The Annotations. The Contractor Shall Maintains An Up-To-Date Knowledge Base And Must Be Able To Update Annotations Of A Patient Report Upon Request. The Contractor Shall At All Times Maintain A Secure Environment And Practice Covering All Protected Health Information (Phi).
- 19 Aug 2019
- The Contractor Shall Provide Enhanced Analysis Of Clinical And Specimen-Derived Data On All Patients Seen At Va Network Hospitals Who Have A Cancer Diagnosis. The Contractor Shall Furnish A Robust, Scalable, Dynamic, Secure, Innovative Solutions Of Analyzing Samples Obtained During Regular Clinical Care Such As Tissues From Biopsy - Using New Genomic Assay Technology. The Clia Vendor Shall Provide Emerging Technologies To Improve Oncology Care For All Patients Within The Va Healthcare System. The Contractor Shall Provide Targeted Sequencing Of Dna Fragments Known To Harbor Mutations In Cancer Specimens (Commonly Referred To As A Mutation Panel). The Number Of Dna Segments Sequenced Varies By The Laboratory And Assay Performed. Mutations In The Dna Can Either Be Inferred Against A Laboratory `Reference Sequence Or Can Be Determined By Sequencing Of Patient Germ-Line Dna Obtained From Adjacent Normal Tissue Or Peripheral Blood. The Contractors Shall Provide Sequencing Of The Whole Exome Of Cancer Specimens, With Mutations Identified By Comparison Against A Laboratory `Reference Sequence Or Germ-Line Dna As Described Above. The Contracotr Shall Provide Sequencing Of The Cancer Specimen Rna Or `Transcriptome . This Strategy Can Be Combined With Either Targeted Or Whole Exome Dna Sequencing. Products Of The Testing Returned To The Va Include All Sequence Data Including Raw Test Data (Fast-Q, Bam, Read Quality Files And Variant Call Files) And A Report Of Important Mutations And Their Significance To Be Returned To The Medical Record. Mutations Found In The Tumor Sample Will Be Annotated So That Clinicians Can Gain An Understanding Of Their Meaning. The Laboratory Shall Specify How This Annotation Will Be Performed And In Particular, What Knowledge Base Will Be Used To Generate The Annotations. The Contractor Shall Maintains An Up-To-Date Knowledge Base And Must Be Able To Update Annotations Of A Patient Report Upon Request. The Contractor Shall At All Times Maintain A Secure Environment And Practice Covering All Protected Health Information (Phi).
- 241-Network Contract Ofc 01(00241)
- Department Of Veterans Affairs (Va)
- $147,900.00
- Department Of Veterans Affairs (Va)
- 36C24519P0761
- Ratification Of Unauthorized Commitment Dna Testing
- 23 Jul 2019
- Ratification Of Unauthorized Commitment Dna Testing
- 245-Network Contract Ofc 5(00245)
- Department Of Veterans Affairs (Va)
- $21,000.00
- Department Of Veterans Affairs (Va)
- 36C24519N0144
- Genomic Testing Services
- 27 Dec 2018
- Genomic Testing Services
- 245-Network Contract Ofc 5(00245)
- Department Of Veterans Affairs (Va)
- $1,805,400.00
- Department Of Veterans Affairs (Va)
- 36C24519D0035
- Genomic Testing Services
- 23 Oct 2018
- Genomic Testing Services
- 245-Network Contract Ofc 5(00245)
- Department Of Veterans Affairs (Va)
- $0.00
- Department Of Veterans Affairs (Va)
- VA24517J1380
- Igf::Ot::Igf Oncology Testing Services
- 21 Aug 2018
- Igf::Ot::Igf Oncology Testing Services
- 245-Network Contract Ofc 5(00245)
- Department Of Veterans Affairs (Va)
- $3,628,450.00
- Department Of Veterans Affairs (Va)
- 36C26320P0567
- Uac Molecular Tissue Testing
- 1 May 2020
- Uac Molecular Tissue Testing
- 263-Nco 23 Consolidate Contr(00263)
- Department Of Veterans Affairs (Va)
- $1,990.00
- Department Of Veterans Affairs (Va)
- VA24117J2259
- Igf::Ot::Igf Genomic Analysis Of Cancerous Tumor Tissue
- 5 Sep 2018
- Igf::Ot::Igf Genomic Analysis Of Cancerous Tumor Tissue
- 241-Network Contract Ofc 01(00241)
- Department Of Veterans Affairs (Va)
- $313,025.00
- Department Of Veterans Affairs (Va)